Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized magnesium sulfate plus albuterol for severe acute asthma attacks in children
IRCT20260420069113N1Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Magnesium sulfate + albuterol with Normal saline + albuterol (2 arms). Primary endpoints: Rate of ICU admission within 24 hours and Duration of hospitalization. Started Oct 2026; status: recruiting.
02
Drugs
magnesium sulfatesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on IRCT20260420069113N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260420069113N1.